Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycoses in the transplanted patient.

M O Dictar1, E Maiolo, B Alexander

  • 1Servicio Infectología y Microbiología Clínica, Instituto A. Fleming, Buenos Aires, Argentina. mdictar@yahoo.com

Medical Mycology
|February 24, 2001
PubMed
Summary

Invasive fungal infections (IFIs) are a significant risk for transplant recipients. Stratifying patients by risk is crucial for effective prophylaxis and treatment strategies against candidiasis and aspergillosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus.

ESMO open·2026
Same author

Flow cytometric PD-L1 expression enhances identification of Reed-Sternberg cells in suspected Hodgkin lymphoma from lymph node biopsies.

Cytometry. Part B, Clinical cytometry·2026
Same author

Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Frontiers in oncology·2026
Same author

Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Frontiers in oncology·2026
Same author

Corrigendum to 'Phosphodiesterase type 5 inhibition as a therapeutic strategy in primary mitochondrial disease: Evidence from patient fibroblasts and clinical observations' [Molecular Genetics and Metabolism Volume 146, Issues 1-2 (2025) Pages 109197].

Molecular genetics and metabolism·2025
Same author

Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Area of Science:

  • Infectious Diseases
  • Transplantation Medicine
  • Mycology

Background:

  • Invasive fungal infections (IFIs) pose a growing threat, particularly to transplant recipients due to immunosuppression.
  • Solid organ transplant recipients (SOTRs) and bone marrow transplant (BMT) patients exhibit varying prevalence rates of IFIs (5-50%).
  • Candida and Aspergillus species are the predominant pathogens, causing over 80% of IFIs in these populations.

Purpose of the Study:

  • To provide an update on recent advances in laboratory diagnosis of candidiasis and aspergillosis in transplant patients.
  • To present findings from multicenter studies on IFIs in SOTR and BMT patients in Argentina.
  • To emphasize the need for improved diagnostic methods for IFIs.

Main Methods:

  • Retrospective and descriptive multicenter studies were conducted.

Related Experiment Videos

  • Analysis of IFIs in 1,861 SOTR patients across four centers.
  • Analysis of IFIs in 2,066 BMT patients from all 12 BMT centers in Argentina.

    • Main Results:

    • IFI prevalence varies significantly among different transplant types.
    • Candida and Aspergillus species are the most common fungal pathogens.
    • Multicenter data from Argentina provide insights into IFI epidemiology in SOTR and BMT patients.

    Conclusions:

    • Transplant recipients are not a homogenous group regarding IFI risk.
    • Stratification of patients based on individual risk degrees is essential.
    • Tailored prophylaxis and treatment strategies are necessary for optimal patient outcomes.